Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.35 |
| ▸ | SELL | P14151 | 1/20 | 0.35 |
| ▸ | SELP | P16109 | 1/20 | 0.35 |
| ▸ | SELE | P16581 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL49544 | 0.82 | CA1 (0.58) | CYP3A4TSHRTDP1CA1CA2 | |
| SCHEMBL13029 | 0.82 | CYP3A4 (0.50) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL12189844 | 0.80 | CYP3A4 (0.43) | CYP3A4TSHRTDP1CA1CA2 | |
| Potassium SCHEMBL31361438 | 0.79 | CYP3A4 (0.48) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| Bromide SCHEMBL4668136 | 0.79 | CYP3A4 (0.48) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL31361467 | 0.79 | CYP3A4 (0.48) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| Lithium SCHEMBL31361451 | 0.79 | CYP3A4 (0.48) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL2050124 | 0.77 | CYP3A4 (0.46) | CYP3A4TSHRTDP1GABRA1GABRB1 | |
| SCHEMBL12217591 | 0.75 | ALDH1A1 (0.52) | TDP1CA1CA2PTGS1PTGS2 | |
| SCHEMBL670489 | 0.75 | CYP3A4 (0.65) | CYP3A4TSHRTDP1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094935-A | Amide prodrugs and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12454511-B2 | 6-methoxy-3,4-dihydro-1H-isoquinolin compounds | ELI LILLY AND COMPANY (US) | 2025-10-28 | — | — | US | disclosed |
| WO-2025049767-A1 | AMIDE PRODRUGS AND USES THEREOF | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| WO-2024208315-A1 | AROMATIC HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2024-10-10 | — | — | WO | disclosed |
| US-20230373927-A1 | 6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUNDS | ELI LILLY AND COMPANY | 2023-11-23 | — | — | US | disclosed |
| EP-4225738-A1 | 6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLINE COMPOUNDS USEFUL IN THE TREATMENT OF DIABETES | Eli Lilly and Company (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116323561-A | 6-methoxy-3, 4-dihydro-1H-isoquinoline compounds useful in the treatment of diabetes | 伊莱利利公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20220056019-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | METACRINE, INC. | 2022-02-24 | — | — | US | disclosed |
| EP-3852736-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | Metacrine, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-113056265-A | Farnesoin X receptor agonists and uses thereof | 梅塔科林公司 | 2021-06-29 | — | — | CN | disclosed |
| WO-2010056194-A1 | 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2010-05-20 | — | — | WO | disclosed |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | ELI LILLY AND COMPANY | 2009-03-12 | — | — | US | disclosed |
| CN-101374808-A | Indole sulfonamide modulators of progesterone receptors | LILLY CO ELI (US) | 2009-02-25 | — | — | CN | disclosed |
| EP-1979314-A2 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | Eli Lilly & Company (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007087488-A9 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | LILLY CO ELI (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007087488-A2 | INDOLE SULFONAMIDE MODULATORS OF PROGESTERONE RECEPTORS | ELI LILLY AND COMPANY (US) | 2007-08-02 | — | — | WO | disclosed |
| EP-0470669-B1 | Preparation of fluorophenols, fluorohalophenols, N-acylfluoroanilines, and N-acylfluorohaloanilines | DOWELANCO (US) | 1997-11-12 | — | — | EP | disclosed |
| US-5164502-A | Fluorinating agents | DOWELANCO (US) | 1992-11-17 | — | — | US | disclosed |
| US-5116982-A | Fluorination | DOWELANCO (US) | 1992-05-26 | — | — | US | disclosed |
| EP-0470669-A2 | Preparation of fluorophenols, fluorohalophenols, N-acylfluoroanilines, and N-acylfluorohaloanilines | DOWELANCO (US) | 1992-02-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056019-A1 | FARNESOID X RECEPTOR AGONISTS AND USES THEREOF | NR1H4, NR1H2, NR1H3 | CYP3A4 586/4885TSHR 365/4885TDP1 3839/4885 |
| US-20230373927-A1 | 6-METHOXY-3,4-DIHYDRO-1H-ISOQUINOLIN COMPOUNDS | GLP1R, GIPR, GPR119 | CYP3A4 2870/4885TSHR 207/4885TDP1 4753/4885 |
| US-20090069400-A1 | Indole Sulfonamide Modulators of Progesterone Receptors | PGR, NPSR1, PRLHR | CYP3A4 475/4885TSHR 22/4885TDP1 2892/4885 |
| US-12454511-B2 | 6-methoxy-3,4-dihydro-1H-isoquinolin compounds | GLP1R, GIPR, GPR119 | CYP3A4 2870/4885TSHR 207/4885TDP1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.